Cannabics Pharmaceuticals

99 articles about Cannabics Pharmaceuticals

• /C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./

  11/28/2018

  In the news release, Cannabics Pharmaceuticals Announces New Provisional Patent Application for Magnetic Targeting of Cannabinoids, issued Nov. 28, 2018 by Cannabics Pharmaceuticals Inc. over PR Newswire, we are advised by the company that the original release was issued inadvertently with imprecise information.

• CEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California

  11/27/2018

  Cannabics Pharmaceuticals Inc. today announced that Mr. Eyal Barad, CEO, will be presenting at the LD Micro Main Event.

• CEO of Cannabics Pharmaceutical Speaking at MJBizCon 2018 in Las Vegas

  11/1/2018

   Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced their CEO, Eyal Barad, will speak on a panel at the Marijuana Business Conference

• Cannabics Pharmaceuticals Granted Patent in South Africa for Its Personalized Cannabinoid Based Diagnostics

  10/25/2018

  Cannabics Pharmaceuticals Inc. announced today that it has been granted its patent for its core technology by the South Africa Patent Office.

• Cannabics Pharmaceuticals Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

  10/16/2018

  Preliminary findings showed more than 80 percent of patients had increase in appetite and 60 percent of patients had over 10 percent weight increase

• Join Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018

  10/9/2018

  Cannabics Pharmaceuticals Inc. announced today that members of its management team will be attending the 3rd CannX Medical Cannabis Conference, to be held in the Tel Aviv Convention Centre, on October 14th – 16th  2018, and will be available for one-on-one meetings.

• Eroll Grow Tech (Seedo) Merges Its Activities With GRCR Partners; Cannabics Pharmaceuticals to Own 13.6% in the Merged Company

  9/18/2018

  GRCR is traded on the OTC stock Exchange

• Cannabics Pharmaceuticals Receives Positive Results in the Development of Cannabinoid-anticancer Drugs

  9/14/2018

  Cannabics Pharmaceuticals (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced it has received encouraging results in its preclinical study showing one of its proprietary cannabinoid compounds causing higher rate of cancer cell death compared to traditional chemotherapy (fig.1).

• Cannabics Pharmaceuticals Granted Patent in Israel for Its Core Technology for Personalized Cannabinoid Based Medicine

  9/5/2018

  Cannabics Pharmaceuticals Inc. has been granted its patent for its core technology by the Israeli Patent Office.

• Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices

  8/22/2018

  Seedo will end pre-sales on September 12th and commence delivery in the next coming weeks

• Cannabics Pharmaceuticals Partners with Eroll Grow Tech to Create First Auto-Grow Device for Medical Cannabis

  8/14/2018

  Companies will develop controlled propagation facilities for the medical cannabis industry

• Cannabics Pharmaceuticals Announces Attendance at the Benzinga Cannabis Capital Conference

  8/10/2018

  Cannabics Pharmaceuticals Inc. announced today that its CEO, Mr. Eyal Barad, will be attending the Benzinga Cannabis Capital Conference, to be held at the Toronto Arcadian Centre, on August 16th-17th 2018, and will be available for one on one meetings.

• Cannabics Pharmaceuticals' CEO Issues Letter to Shareholders

  8/2/2018

  "Exploring complementary Disruptive Technologies to add to our core Science"

• Join Cannabics Pharmaceuticals at the National Cannabis Industry Association's Cannabis Business Summit and Expo Held at San Jose Convention Center, California USA, July 25-27, 2018

  7/11/2018

  Cannabics Pharmaceuticals Inc. announced that senior members of its team will be attending the National Cannabis Industry Association Business Conference and Expo, to be held in San Jose convention center, California, USA, on July 25th-27th 2018, and will be available for one on one meetings.

• Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)

  7/3/2018

  Cannabics Pharmaceuticals Inc. announced that it has concluded its clinical trial held at Rambam Medical Center.

• Cannabics Pharmaceuticals Enters a Memorandum of Understanding With Clinical-Stage Biopharmaceutical Company Focused on the Treatment of Ophthalmic Disorders

  6/29/2018

  Cannabics Pharmaceuticals Inc. announced that it has entered a memorandum of understanding with a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders.

• Cannabics Pharmaceuticals Announces Collaboration With Life Source Partners CEO Muriel Zohar to Optimize Technology Applications and Evaluate New Opportunities

  5/2/2018

  Dr. Zohar will support strategic business planning as Cannabics enters $10 million Standby Equity Distribution Agreement with YAII PN, Ltd.

• Cannabics Pharmaceuticals Announces New Technology Patent

  4/18/2018

  Cannabics patent granted with enabling technology to personalize Cannabinoid diagnostics and treatment for Cancer patients

• Cannabics Pharmaceuticals Hires Chief Data Officer to Address Industry Compliance and Utilization/Analytics Application

  2/20/2018

  Cannabics Pharmaceuticals announced the appointment of Yasha Borstein as the company's Chief Data Officer.

• Cannabics Pharma Files an International Patent Application on Methods for Testing and Predicting Therapeutic Effectiveness of Cannabinoids for Cancer Patients

  1/2/2018

  Cannabics Pharmaceuticals announced today that it has filed an international patent application with the PCT authorities on methods for testing which cannabinoids or combinations of cannabinoids are likely be effective in individual patients.